Where does Mineralys Therapeutics, Inc.'s cash flow data come from?

Every line is extracted from Mineralys Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	Q1 '26	Q4 '25	Q3 '25	Q2 '25	Q1 '25
Net income	-$39.34M-22.0%	-$32.23M+12.7%	-$36.93M+14.7%	-$43.27M-2.5%	-$42.21M+13.8%
Depreciation and amortization	$6K-53.8%	$13K-13.3%	$15K-6.3%	$16K+6.7%	$15K0.0%
Stock-based compensation	$6.55M+23.9%	$5.29M-9.5%	$5.84M+28.3%	$4.55M+24.9%	$3.65M+16.3%
Change in accounts payable	-$402K—	——	$1.03M-88.6%	$9.07M+687%	-$1.55M—
Change in other assets	$1.95M+224%	-$1.57M+56.0%	-$3.56M-105%	-$1.74M-140%	$4.4M—
Change in accrued investment income	-$289K-260%	$181K+1,910%	-$10K-121%	$47K+190%	-$52K+46.9%
Net cash from operating activities	-$39.47M-4.2%	-$37.89M-31.2%	-$28.87M+4.3%	-$30.17M+33.7%	-$45.49M+31.9%
Proceeds from maturities/sales of investments	$302.5M+83.3%	$165M+10.0%	$150M+100%	$75M+114%	$35M-76.3%
Purchases of fixed maturity securities	$347.44M+29.4%	$268.47M-10.7%	$300.51M+155%	$117.88M-7.8%	$127.88M+100%
Net cash from investing activities	-$44.94M+56.6%	-$103.49M+31.2%	-$150.51M-251%	-$42.88M+53.8%	-$92.88M-211%
Proceeds from issuance of common stock	$4.06M-18.2%	$4.96M-25.1%	$6.62M—	——	$189.17M+350,207%
Net cash from financing activities	$24.27M-74.9%	$96.7M-67.2%	$295.19M+2,903%	$9.83M-94.8%	$189.28M+210,210%
Net increase (decrease) in cash	-$60.14M—	——	$115.81M+283%	-$63.22M-224%	$50.92M+203%
Accretion (Amortization) of Discounts and Premiums, Investments	$4.63M+9.9%	$4.21M+75.6%	$2.4M+7.5%	$2.23M+113%	$1.05M-21.8%
Increase (Decrease) in Accrued Interest Receivable, Net	-$289K-260%	$181K+1,910%	-$10K-121%	$47K+190%	-$52K+46.9%
Increase (Decrease) in Prepaid Expense and Other Assets	$1.95M+224%	-$1.57M+56.0%	-$3.56M-105%	-$1.74M-140%	$4.4M—
Payments to Acquire Held-to-Maturity Securities	$347.44M+29.4%	$268.47M-10.7%	$300.51M+155%	$117.88M-7.8%	$127.88M+100%
Payments Of Stock Issuance Costs	$1K-99.7%	$305K+952%	$29K-38.3%	$47K+370%	$10K-78.7%
Public offering and shelf offering costs included in accounts payable and accrued liabilities	$7K—	——	$304K—	——	$289K—
Free cash flow	——	-$37.9M-31.3%	-$28.87M+4.3%	-$30.17M+33.7%	-$45.49M+31.9%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Mineralys Therapeutics, Inc.'s cash flow data come from?: Every line is extracted from Mineralys Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.